Imran Nazeer, MD
Nephrology · Lufkin, TXNPI 1477582039
Payments from drug & device makers
Across 264 payments — averaging $2171.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$363K
- Boehringer Ingelheim$125K
- Boehringer Ingelheim Pharma GmbH & Co.kg$40K
- AstraZeneca$34K
- Boehringer Ingelheim International GmbH$8K
- ANI Pharmaceuticals, Inc.$439
- plus $3K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 79 | $362,921 |
| Boehringer Ingelheim | 13 | $125,287 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $40,062 |
| AstraZeneca | 36 | $34,422 |
| Boehringer Ingelheim International GmbH | 4 | $7,663 |
| ANI Pharmaceuticals, Inc. | 9 | $439 |
| Bayer | 15 | $361 |
| Amgen(2 entities) | 16 | $319 |
| Calliditas Therapeutics US Inc. | 11 | $234 |
| Vifor Pharma, Inc. | 10 | $212 |
| Novartis | 9 | $200 |
| Johnson & Johnson | 10 | $168 |
| Aurinia Pharma U.S., Inc. | 6 | $119 |
| Pfizer | 1 | $114 |
| Mallinckrodt Hospital Products Inc. | 6 | $105 |
| Mallinckrodt Enterprises LLC | 6 | $99 |
| Ardelyx, Inc. | 4 | $93 |
| Radius Health, Inc. | 5 | $80 |
| Shield Therapeutics Inc | 3 | $79 |
| Travere Therapeutics, Inc. | 6 | $74 |
| Novo Nordisk | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Boston Scientific | 1 | $36 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $31 |
| Akebia Therapeutics Inc | 2 | $28 |
| Cormedix Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Sandoz | 1 | $21 |
| Philips North America LLC | 1 | $16 |
| Medtronic | 1 | $16 |
| Nxstage Medical, Inc. | 1 | $12 |
How this compares
$573,346 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Lufkin
- Prashant KumarLufkin$329K
- Pablo PergolaSan Antonio$14.2M
- German HernandezEl Paso$9.7M
- Sreedhar MandayamHouston$7M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Marializa BernardoHouston$4.2M
- Judith BettsAustin$3.7M
- Wesley CalhounSan Antonio$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.